Botulinum Toxin Index
Botulinum Toxin Index connects product identities, company roles, regional approvals, scientific concepts, clinical-use context, and the people and organizations that have shaped the field. The emphasis is on relationships that are easy to blur: developer versus manufacturer, owner versus commercialization partner, global brand name versus local label, and clinical discussion versus an approved indication.
Explore the Index
Section titled “Explore the Index”| Area | What it connects | Start here |
|---|---|---|
| Companies | Developers, manufacturers, owners, approval holders, and commercialization partners | Company directory |
| Industry | Market-size estimates, growth forecasts, revenue measures, and competitive relationships | Botulinum toxin market |
| Brands and products | Product identity, toxin type, formulation context, regional names, and company relationships | Brand directory |
| Regulatory reference | Historical U.S. approval anchors, current product-specific labels, and non-approved application stages | FDA approval timeline, FDA indication matrix, and U.S. regulatory status |
| Science | Toxin biology, serotypes, mechanism, diffusion, immunogenicity, and comparison limits | Botulinum toxin |
| Clinical context | Conditions, treatment goals, label boundaries, units, handling, anatomy, and safety interpretation | Clinical uses and clinical practice |
| Industry network | Scientists, physicians, executives, societies, congresses, and market-facing events | People and organizations and events |
Key Reference Datasets
Section titled “Key Reference Datasets”| Reference | Question it helps answer | Scope |
|---|---|---|
| Brand-to-company map | Who developed, manufactures, owns, or commercializes a product? | Major represented product families and the distinct roles of related companies |
| Brand directory | Which ingredients, toxin types, and companies connect to each brand? | Product identities and company roles across regional markets |
| U.S. FDA indication matrix | Which current U.S. labels include a particular indication or patient population? | Product-specific labeled uses; not a universal clinical-use table |
| U.S. FDA approval timeline | When did major U.S. regulatory milestones occur? | Historical approval anchors separated from current label evidence |
| U.S. botulinum toxin regulatory status | Which products are FDA approved, and which public programs remain at CRL or resubmission-planning stages? | Current U.S. stage without treating a filing, CRL response, or planned resubmission as approval |
| Type A vs type B | How do serotypes, products, units, and clinical roles differ? | Biological and regulatory comparison without implying substitutability |
How Products Connect
Section titled “How Products Connect”| Product or family | Connected companies | Relationship |
|---|---|---|
| Botox / Botox Cosmetic | AbbVie / Allergan | Allergan built the franchise; AbbVie is the current parent-company context. |
| Dysport | Ipsen and Galderma | Ipsen is tied to product origin and the therapeutic business, while Galderma commercializes aesthetic Dysport-family products in licensed territories. |
| Jeuveau / Nabota | Daewoong Pharmaceutical and Evolus | Daewoong manufactures the product; Evolus commercializes Jeuveau in the United States and Nuceiva in selected international markets. |
| Daxxify | Revance (formerly Crown Laboratories) | Revance Therapeutics developed Daxxify. Crown acquired Revance Therapeutics in February 2025, then adopted Revance as the combined company’s operating name on March 31, 2025. (Revance name-transition announcement 🔗) |
| Letybo / Botulax | Hugel | One Korea-origin product family appears under different names and regulatory contexts across markets. |
These relationships describe industry structure, not clinical rank. A shared company, toxin type, or product-family history does not establish identical labels, formulations, indications, units, safety profiles, or clinical performance.
Sources and Status
Section titled “Sources and Status”Medical, regulatory, formulation, approval, and product-specific claims are linked where appropriate to prescribing information, regulator records, peer-reviewed literature, and official company disclosures. Changing information such as approvals, ownership, leadership, and market availability should be read with the stated market, source date, and status context attached.

